SCHEMBL1093571

SCHEMBL1093571

N#Cc1cccc(S(=O)(=O)Nc2nccs2)c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 1/20 0.56
SLC40A1 Q9NP59 1/20 0.56
SCN9A Q15858 12/20 0.56
ALDH1A1 P00352 4/20 0.53
LMNA P02545 2/20 0.53
KDM4E B2RXH2 1/20 0.53
CYP2C9 P11712 1/20 0.53
EDNRA P25101 1/20 0.53
SLC6A4 P31645 1/20 0.53
ADRA1A P35348 1/20 0.53
PRMT6 Q96LA8 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
PKM P14618 3/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
SCN5A Q14524 1/20 0.53
SLC22A12 Q96S37 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1349619 0.83 ALDH1A1 (0.67) SCN9AALDH1A1LMNAKDM4ECYP2C9
SCHEMBL1094871 0.80 ALDH1A1 (0.57) SCN9AALDH1A1LMNAKDM4ECYP2C9
SCHEMBL1576750 0.80 ALDH1A1 (0.57) SCN9AALDH1A1LMNAKDM4ECYP2C9
SCHEMBL9301181 0.80 ALDH1A1 (0.69) SCN9AALDH1A1LMNAKDM4ECYP2C9
SCHEMBL19613863 0.80 LMNA (0.69) SCN9AALDH1A1LMNAKDM4ECYP2C9
SCHEMBL13230136 0.80 PKM (0.60) SLC40A1SCN9AALDH1A1LMNAKDM4E
SCHEMBL1094451 0.79 SCN9A (0.62) GLO1SLC40A1SCN9ASCN5ASLC22A12
SCHEMBL1094038 0.79 AKT1 (0.53) GLO1SLC40A1SCN9AMEN1KMT2A
SCHEMBL326633 0.78 ALDH1A1 (0.71) SCN9AALDH1A1LMNAKDM4ECYP2C9
SCHEMBL3159069 0.78 SCN3A (0.73) ALDH1A1LMNAPKMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8907101-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2014-12-09 US disclosed
US-20130338111-A1 Sulfonamide Derivatives ICAGEN, INC. (US) 2013-12-19 US disclosed
US-8541588-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2013-09-24 US disclosed
US-20120149679-A1 Sulfonamide Derivatives ICAGEN, INC. 2012-06-14 US disclosed
US-8153814-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2012-04-10 US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 GLO1 2222/4885SLC40A1 3958/4885SCN9A 73/4885
US-20130338111-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 GLO1 2222/4885SLC40A1 3958/4885SCN9A 73/4885
US-20120149679-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 GLO1 2222/4885SLC40A1 3958/4885SCN9A 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.